RT Journal Article
SR Electronic
T1 A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP P181
DO 10.1186/2051-1426-3-S2-P181
VO 3
IS Suppl 2
A1 Long, Georgina V
A1 Dummer, Reinhard
A1 Ribas, Antoni
A1 Puzanov, Igor
A1 Michielin, Olivier
A1 VanderWalde, Ari
A1 Andtbacka, Robert HI
A1 Cebon, Jonathan
A1 Fernandez, Eugenio
A1 Malvehy, Josep
A1 Olszanski, Anthony J
A1 Gajewski, Thomas F
A1 Kirkwood, John M
A1 Kuznetsova, Olga
A1 Chen, Lisa
A1 Kaufman, David R
A1 Chou, Jeffrey
A1 Hodi, F Stephen
YR 2015
UL http://jitc.bmj.com/content/3/Suppl_2/P181.abstract